Curative Creates Sensible Diagnostics Spin-Off

Curative Inc., a health services company, has announced Sensible Diagnostics, a spin-off whose aim is to commercialize their point-of-care PCR testing platform.
 
The new Sensible PCR Platform (which was designed to support Curative’s legacy next-generation testing operations) combines speed, affordability, and accuracy, making it an easy drop-in upgrade for current point-of-care testing workflows. With a 10-minute time-to-result, market-leading test pricing, and lab-quality PCR results, the Sensible Platform is poised to change the current standard of care.
 
“We are excited to be rolling out Sensible Diagnostics to bring a revolutionary, efficient PCR 10-minute desktop testing platform to the masses,” said Fred Turner, CEO and co-founder of Curative. “This device is truly a game changer for diagnostics testing in retail clinics, urgent care, and beyond, and will provide fast, accurate, and affordable results.”

Supplanting the Lateral Flow Immunoassay

Since the ‘80s, lateral flow immunoassay technology has dominated the infectious disease testing market. While it offers a relatively inexpensive result in a compact package, it is common knowledge that this technology is inaccurate and is prone to user errors due to its manual workflow. Despite this, PCR has yet to supplant the lateral flow immunoassay as the go-to, point-of-care testing technology because of its high costs and relative operational complexity.
 
The Sensible Diagnostics Platform was built based on over two years of experience performing over 2 million molecular point-of-care tests in the field while part of Curative’s initial diagnostic focus. Sensible’s design is simple: fewer parts and fewer process steps, which means fewer mistakes and safer, more affordable results. With prices that are competitive with lateral flow antigen testing, Sensible Diagnostics’ platform is setting out to make lateral flow immunoassay testing a thing of the past.
 
“We learned a lot about diagnostics testing from the pandemic, and in conjunction with our extensive knowledge in the field, we wanted to build a PCR testing platform that would deliver on speed and accuracy while keeping costs low,” said Ernest Templin, CEO and co-founder of Sensible Diagnostics. ”This platform has a pricing structure that is competitive with lateral flow testing and delivers a PCR test result that is exactly the same as one you would get from a lab. We are providers who built this platform for providers, so patients can be offered a faster and more accurate test that has better technology without increasing their healthcare costs.”
 
Sensible Diagnostics’ co-founders Ernest Templin, CEO, and Mark Kelleher, PhD, MBA, COO / CSO, lead a team that brings years of combined industry experience and hands-on pandemic experience. The company’s platform will be launched with a respiratory test but was built to be extended to all types of infectious disease testing, like STIs. In addition to government grant money provided, the company is currently about to launch a Series A funding round.